ArticleTransgender health2026
Alterations in Body Fat and Composition Among Thai Transmasculine Individuals Undergoing Short-Term Testosterone Therapy.
Article in Transgender health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to investigate the early impacts of masculinizing hormone therapy on body composition among testosterone-naive Thai transmasculine (TM) individuals, focusing on changes in fat and lean mass within the initial 3-6 months of treatment. Methods: In total, 32 participants were enrolled in this prospective study, receiving a 6-month course of 250-mg intramuscular testosterone enanthate. The assessment included whole-body dual X-ray absorptiometry, alongside anthropometric and laboratory evaluations. Results: After 6 months of testosterone administration, a significant reduction in total fat mass (FM) was observed (-4.5%; 95% confidence interval [CI] -8.5 to -0.5). Concurrently, there was an increase in total fat-free mass (FFM) (7.0%; 95% CI 3.3 to 10.8). Stratifying participants based on the World Health Organization Asian obesity criteria (body mass index <23 kg/m Conclusions: Within a brief timeframe of testosterone therapy, a substantial decrease in FM and an increase in FFM were noted. Notably, this reduction in FM was more prominent in participants with obesity. Various alterations in laboratory parameters, such as hemoconcentration, reduced HDL-C, and diminished SHBG, were attributed to changes in hepatic metabolism and pituitary suppression induced by exogenous testosterone. These findings contribute valuable insights into the nuanced effects of hormone therapy on body composition among the TM population. Clinical Trial Registration Number-TCTR20241004001.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.